Haleon PLC
HLN
View Detailed Chart
9.810USD
-0.060-0.61%
Close 09/12, 16:00（ET）Quotes delayed by 15 min
88.14BMarket Cap
61.12P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.61%
5 Days
+0.10%
1 Month
+1.13%
6 Months
-3.35%
Year to Date
+2.83%
1 Year
-6.66%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-12Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
5
analysts
Buy
Current Rating
11.007
Target Price
+12.20%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Haleon plc is a consumer healthcare company. The Company's product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 31.54.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 41.40%.
Undervalued
The company’s latest PE is 58.37, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 577.49M shares, decreasing 24.84% quarter-over-quarter.
Held by Van Duyn Dodge & E. Morris Cox
Star Investor Van Duyn Dodge & E. Morris Cox holds 155.47M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.10.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Haleon plc is a consumer healthcare company. The Company's product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.
Ticker SymbolHLN
CompanyHaleon PLC
CEOMr. Brian Mcnamara
Websitehttps://www.haleon.com/
Related Instruments
-0.17%
-0.24%
-0.84%
-1.90%
-2.80%
-2.72%
+1.14%
-2.24%
-2.81%
-3.94%
-1.30%
-0.77%
-2.81%
-1.23%
-1.52%
+0.03%
-1.60%
-0.60%
-1.44%
-0.15%
